ABVX.PA,ADHD,ADMA,ADXN.SW,ADXS,AGLE,AIMT,AKAO,ALBO,ALNEV.PA,ALSEN.PA,APOP,ARDM,AUPH,AZRX,BCLI,BDSI,BLFS,BLPH,BTX,CBAY,CBIO,CLCD,CTDH,DMPI,EIGR,EVGN,FOMX,GEMP,HRTX,IMNP,IVA.PA,KMDA,KTOV,LJPC,MATN,MNOV,OCRX,OHRP,ONCS,ONTX,ORPN,PRTA,PRTK,PTN,PTX,RMTI,RNN,RXDX,SCLN,SSKN,STML,TCON,THLD,TIG,VBIV,VBLT,VRML,WINT,ZGNX -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is Advaxis Inc (NASDAQ:ADXS) As Financially Strong As Its Balance Sheet Indicates?
    Simply Wall St.12 hours ago

    Is Advaxis Inc (NASDAQ:ADXS) As Financially Strong As Its Balance Sheet Indicates?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Advaxis Inc (NASDAQ:ADXS), as the company does not have to adhere to strict debt covenants. However, it also faces higherRead More...

  • Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?
    Simply Wall St.12 hours ago

    Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations?

    Aeglea Biotherapeutics Inc (NASDAQ:AGLE), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is AGLERead More...

  • Capital Cube17 hours ago

    ETFs with exposure to Evogene Ltd. : December 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Evogene Ltd. Here are 5 ETFs with the largest exposure to EVGN-US. Comparing the performance and risk of Evogene Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Zacks Small Cap Research19 hours ago

    MNOV: Positive Topline Results for MN-166 in P2 ALS Study

    The primary endpoint of the study (safety and tolerability) was achieved and there were efficacy trends in key functional secondary endpoints that favored MN-166. This was a single center, double blind, placebo controlled six-month study with patients randomized 2:1 to receive riluzole (100 mg/day) plus either MN-166 (60 mg/day) or placebo. The six-month double blind portion was followed by a six-month open label extension phase during which all patients received MN-166.

  • TheStreet.com19 hours ago

    Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

    The republican loss in the Alabama special election for U.S. senate had only a brief imapct on stock futures.

  • Zacks21 hours ago

    These 5 Stocks Have Popped More Than 100% Since Trump's Win

    With tax cuts close to becoming law, it makes sense to pick stocks that have posted stellar performances since Trump's win.

  • MarketWatch22 hours ago

    Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment

    Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said data from the trial ...

  • Should BioLife Solutions Inc’s (undefined:BLFS) Earnings Decline In Recent Times Worry You?
    Simply Wall St.22 hours ago

    Should BioLife Solutions Inc’s (undefined:BLFS) Earnings Decline In Recent Times Worry You?

    When BioLife Solutions Inc (NASDAQ:BLFS) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...

  • Want To Invest In Ocera Therapeutics Inc (undefined:OCRX)? Here’s How It Performed Lately
    Simply Wall St.23 hours ago

    Want To Invest In Ocera Therapeutics Inc (undefined:OCRX)? Here’s How It Performed Lately

    For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...

  • Capital Cube2 days ago

    ETFs with exposure to Rockwell Medical, Inc. : December 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Rockwell Medical, Inc. Here are 5 ETFs with the largest exposure to RMTI-US. Comparing the performance and risk of Rockwell Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube2 days ago

    ETFs with exposure to Kamada Ltd. : December 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Kamada Ltd. Here are 5 ETFs with the largest exposure to KMDA-US. Comparing the performance and risk of Kamada Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 days ago

    ETFs with exposure to Aradigm Corp. : December 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aradigm Corp. Here are 5 ETFs with the largest exposure to ARDM-US. Comparing the performance and risk of Aradigm Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index
    SmarterAnalyst2 days ago

    Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index

    Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced today that its common stock has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective before market open on Monday, December 18 2017.

  • Best-In-Class NasdaqGM Growth Stocks
    Simply Wall St.4 days ago

    Best-In-Class NasdaqGM Growth Stocks

    Investors seeking to increase their exposure to growth should consider companies such as Supernus Pharmaceuticals and Sandy Spring Bancorp. Analysts are generally optimistic about the future of these stocks, basedRead More...

  • Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?
    Simply Wall St.5 days ago

    Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?

    In September 2017, Onconova Therapeutics Inc (NASDAQ:ONTX) announced its latest earnings update. Overall, the consensus outlook from analysts appear pessimistic, as a -17.46% fall in profits is expected in theRead More...

  • Here's What's Causing Investors to Sell La Jolla Pharmaceutical Shares Today
    Motley Fool6 days ago

    Here's What's Causing Investors to Sell La Jolla Pharmaceutical Shares Today

    The company's making progress toward an FDA decision on its lead drug candidate, but that's not enough to keep investors happy.

  • Should You Be Concerned About DelMar Pharmaceuticals Inc’s (DMPI) Shareholders?
    Simply Wall St.6 days ago

    Should You Be Concerned About DelMar Pharmaceuticals Inc’s (DMPI) Shareholders?

    I am going to take a deep dive into DelMar Pharmaceuticals Inc’s (NASDAQ:DMPI) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...

  • 7 ‘Strong Buy’ Disruptive Stocks You Should Track Now
    InvestorPlace6 days ago

    7 ‘Strong Buy’ Disruptive Stocks You Should Track Now

    All these stocks have a ‘Strong Buy’ rating from the best-performing analysts on TipRanks and big upside potential from the current share price. CBS Insights analyzed earning call transcripts and found that Amazon’s name cropped up over 3,000 times in just one year! The list of companies mentioning AMZN span all the way from the pharmacy industry to the retail, logistics and content industries. Last week, Amazon held its much-hyped cloud conference AWS re:Invent 2017 in Las Vegas.

  • MarketWatch6 days ago

    MediciNova stock up more than 50% on positive trial results

    Biotech company MediciNova Inc. said late Thursday that it had received positive top-line results from the company's clinical trial of MN-166 in amyotrophic lateral sclerosis. Shares went on a rampage ...

  • Capital Cube7 days ago

    ETFs with exposure to BioTime, Inc. : December 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioTime, Inc. Here are 5 ETFs with the largest exposure to BTX-US. Comparing the performance and risk of BioTime, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube8 days ago

    Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : December 6, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Zogenix, Inc. a score of 16. Our analysis is based on comparing Zogenix, Inc. with the following peers – DURECT Corporation, Mallinckrodt Plc, Merck & Co., Inc., Antares Pharma, Inc., Nektar Therapeutics, Johnson & Johnson, Cardinal Health, Inc., Eli Lilly and Company, Alkermes Plc and Pfizer Inc. ... Read more (Read more...)

  • Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : December 6, 2017
    Capital Cube8 days ago

    Heron Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HRTX-US : December 6, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Heron Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • 5 Key Things to Know About This Leading Marijuana Stock's Future
    Motley Fool8 days ago

    5 Key Things to Know About This Leading Marijuana Stock's Future

    GW Pharmaceuticals' executives on what's next for Epidiolex and the biotech's other pipeline cannabinoids.

  • Why Heron Therapeutics Stock Is Crashing Today
    Motley Fool9 days ago

    Why Heron Therapeutics Stock Is Crashing Today

    Heron bolsters its shrinking cash position with a $150 million public offering.